NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free LGND Stock Alerts $72.14 +1.05 (+1.48%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$70.11▼$73.6550-Day Range$70.86▼$89.2052-Week Range$49.24▼$94.57Volume182,456 shsAverage Volume164,444 shsMarket Capitalization$1.28 billionP/E Ratio26.23Dividend YieldN/APrice Target$116.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ligand Pharmaceuticals alerts: Email Address Ligand Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside61.3% Upside$116.33 Price TargetShort InterestHealthy4.59% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment1.04Based on 5 Articles This WeekInsider TradingSelling Shares$153,034 Sold Last QuarterProj. Earnings Growth16.84%From $2.91 to $3.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.98 out of 5 starsMedical Sector8th out of 947 stocksPharmaceutical Preparations Industry4th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $116.33, Ligand Pharmaceuticals has a forecasted upside of 61.3% from its current price of $72.14.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.59% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 14.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 3.9 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest7 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows5 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $153,034.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.19% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 16.84% in the coming year, from $2.91 to $3.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 26.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 156.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 26.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 255.06.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Ligand Pharmaceuticals Stock (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More LGND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesMarch 17, 2024 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Stephen L. Sabba Sells 1,893 SharesMarch 16, 2024 | finance.yahoo.comLGND Apr 2024 70.000 putMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 16, 2024 | finance.yahoo.comLGND Apr 2024 110.000 callMarch 16, 2024 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Sees Significant Drop in Short InterestMarch 10, 2024 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $140,649.90 in StockMarch 6, 2024 | uk.finance.yahoo.comLigand Pharmaceuticals Incorporated (LGND)March 5, 2024 | businesswire.comLigand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare ConferenceMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 4, 2024 | businesswire.comLigand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 3, 2024 | ca.finance.yahoo.comLGND Aug 2024 110.000 callMarch 3, 2024 | ca.finance.yahoo.comLGND Apr 2024 90.000 callFebruary 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)February 28, 2024 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comLigand Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsFebruary 27, 2024 | msn.comWhy Is Ligand Pharmaceuticals Stock Trading Higher Today?February 27, 2024 | finance.yahoo.comLigand Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Reports Solid Earnings Amidst Operational TransformationFebruary 27, 2024 | businesswire.comLigand Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | benzinga.comLigand Pharmaceuticals's Earnings: A PreviewFebruary 26, 2024 | msn.comLigand Pharmaceuticals Q4 2023 Earnings PreviewFebruary 23, 2024 | finance.yahoo.comLGND Mar 2024 65.000 putFebruary 22, 2024 | msn.comEsai gets Japanese approval for epilepsy drug using Ligand technologyFebruary 22, 2024 | businesswire.comLigand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®February 20, 2024 | finance.yahoo.comWhy Ligand Pharmaceuticals (LGND) Dipped More Than Broader Market TodayFebruary 16, 2024 | businesswire.comLigand Pharmaceuticals Expands Senior Leadership Team with Two Key HiresFebruary 13, 2024 | finance.yahoo.comLigand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024See More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees58Year FoundedN/APrice Target and Rating Average Stock Price Target$116.33 High Stock Price Target$144.00 Low Stock Price Target$95.00 Potential Upside/Downside+61.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.75 Trailing P/E Ratio26.23 Forward P/E Ratio24.79 P/E GrowthN/ANet Income$52.15 million Net Margins37.80% Pretax Margin48.48% Return on Equity11.98% Return on Assets10.27% Debt Debt-to-Equity RatioN/A Current Ratio14.15 Quick Ratio12.72 Sales & Book Value Annual Sales$131.31 million Price / Sales9.72 Cash Flow$5.02 per share Price / Cash Flow14.38 Book Value$40.39 per share Price / Book1.79Miscellaneous Outstanding Shares17,700,000Free Float15,864,000Market Cap$1.28 billion OptionableOptionable Beta1.02 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Todd C. Davis Ph.D. (Age 63)CEO & Director Comp: $743.49kMr. Matthew E. Korenberg (Age 49)President & COO Comp: $760.99kMr. Octavio Espinoza (Age 53)Chief Financial Officer Comp: $457.19kMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Comp: $480.16kMr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More ExecutivesKey CompetitorsMannKindNASDAQ:MNKDIronwood PharmaceuticalsNASDAQ:IRWDGeronNASDAQ:GERNInnovivaNASDAQ:INVADynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 24,653 shares on 3/11/2024Ownership: 10.602%Fisher Asset Management LLCBought 16,035 shares on 3/5/2024Ownership: 0.279%Stephen L SabbaSold 1,893 sharesTotal: $140,649.90 ($74.30/share)Wellington Management Group LLPBought 14,687 shares on 3/5/2024Ownership: 0.083%Octavio EspinozaSold 140 sharesTotal: $12,384.40 ($88.46/share)View All Insider TransactionsView All Institutional Transactions LGND Stock Analysis - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price target for 2024? 3 Wall Street research analysts have issued 12 month price objectives for Ligand Pharmaceuticals' shares. Their LGND share price targets range from $95.00 to $144.00. On average, they predict the company's share price to reach $116.33 in the next year. This suggests a possible upside of 61.3% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2024? Ligand Pharmaceuticals' stock was trading at $71.42 at the beginning of 2024. Since then, LGND stock has increased by 1.0% and is now trading at $72.14. View the best growth stocks for 2024 here. Are investors shorting Ligand Pharmaceuticals? Ligand Pharmaceuticals saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 762,600 shares, a decrease of 14.9% from the February 14th total of 896,600 shares. Based on an average daily trading volume, of 143,000 shares, the short-interest ratio is presently 5.3 days. Approximately 4.6% of the company's stock are short sold. View Ligand Pharmaceuticals' Short Interest. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its earnings results on Wednesday, November, 8th. The biotechnology company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.34. The biotechnology company had revenue of $32.87 million for the quarter, compared to the consensus estimate of $27.22 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 11.98% and a net margin of 37.80%. Ligand Pharmaceuticals's revenue for the quarter was down 44.5% on a year-over-year basis. During the same period last year, the business posted ($0.20) earnings per share. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY24 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $4.25 to $4.75 for the period, compared to the consensus estimate of $4.28. The company issued revenue guidance of $130 million to $142 million, compared to the consensus revenue estimate of $137.66 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.82%), Vanguard Group Inc. (10.60%), Dimensional Fund Advisors LP (3.81%), Stephens Investment Management Group LLC (3.80%), Villere ST Denis J & Co. LLC (2.47%) and Pacer Advisors Inc. (1.88%). Insiders that own company stock include Andrew Reardon, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza, Stephen L Sabba and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGND) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.